Wockhardt Limited — Updates, 07-02-2025: Press Release

Wockhardt Limited reported robust financial results for the third quarter and nine months of FY 2024-25, showcasing significant revenue and EBITDA growth. Revenue for the nine months reached ₹2,290 crore, an 8% year-on-year increase, with Q3 revenue of ₹725 crore, up 2% from Q3 FY24. Notably, EBITDA surged 89% year-on-year in the nine months to ₹339 crore, with Q3 EBITDA climbing 50% to ₹100 crore, reflecting improved margins.

The company is making strides in antibiotic development, with ZAYNICH® showing a clinical cure rate of 96.8% in a pivotal Phase III study, significantly outperforming the gold standard meropenem. The drug is positioned for global health authority applications, indicating potential market introduction soon.

MIQNAF®, recently approved for treating Community-Acquired Bacterial Pneumonia, demonstrated a 96.7% cure rate in clinical trials, addressing critical antibiotic resistance issues in India. The US FDA has granted Fast Track designation to WCK 6777, enhancing its prospects in outpatient therapies.

Overall, Wockhardt's strategic focus on novel therapeutics positions it well for future growth, suggesting a positive outlook for investors.